[Cobimetinib/vemurafenib-associated bilateral serous retinopathy: a case report].
Under a combination therapy with cobimetinib/vemurafenib for the treatment of BRAF-V600 positive metastatic melanoma, symptomatic or asymptomatic bilateral serous retinopathy can occur, which is reversible after dose reduction or treatment discontinuation. In the case presented the progress of bilateral serous retinopathy was documented by optical coherence tomography (OCT). After therapy discontinuation, subfoveal fluid levels varied until remission was reached six months later.